[go: up one dir, main page]

MXPA05008033A - Composiciones de milnacipran en forma de multiparticulas para administracion oral. - Google Patents

Composiciones de milnacipran en forma de multiparticulas para administracion oral.

Info

Publication number
MXPA05008033A
MXPA05008033A MXPA05008033A MXPA05008033A MXPA05008033A MX PA05008033 A MXPA05008033 A MX PA05008033A MX PA05008033 A MXPA05008033 A MX PA05008033A MX PA05008033 A MXPA05008033 A MX PA05008033A MX PA05008033 A MXPA05008033 A MX PA05008033A
Authority
MX
Mexico
Prior art keywords
particles
prepared
coating
drug
polymer
Prior art date
Application number
MXPA05008033A
Other languages
English (en)
Inventor
Raoman V Rariy
Original Assignee
Collegium Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collegium Pharmaceutical Inc filed Critical Collegium Pharmaceutical Inc
Publication of MXPA05008033A publication Critical patent/MXPA05008033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se ha desarrollado una composicion de milnacipran en forma de multiparticulas para administracion oral. La formulacion es elabora complejando el milnacipran con una resina de intercambio ionico en la forma de pequenas particulas, tipicamente de menos de 150 micrones. Las formulaciones en forma de multiparticulas pueden ser de cualquiera de uno o mas de los siguientes tipos de particulas que son formuladas en una forma de dosificacion final: particulas de liberacion inmediata, preparadas por recubrimiento de particulas que contienen el farmaco con el polimero que es insoluble en el medio neutro de la saliva, pero que se disuelven en el medio acido del estomago; particulas con recubrimiento enterico, preparadas por recubrimiento de particulas que contienen el farmaco con el polimero que es insoluble en el medio acido del estomago pero que se disuelven en el medio neutro del intestino delgado; particulas de liberacion prolongada, preparadas por recubrimiento de particulas que contiene el farmaco con un polimero que forma una membrana insoluble en agua pero permeable al agua; particulas de liberacion prolongada con recubrimiento enterico preparadas por recubrimiento de particulas de farmaco de liberacion prolongada con un segundo recubrimiento enterico; particulas de liberacion retardada, preparadas por recubrimiento de particulas que contiene el farmaco con un polimero que es insoluble en el medio acido del estomago y el medio del intestino delgado superior, pero que se disuelven en el intestino delgado inferior o el intestino grueso superior. Las varias particulas que contiene el farmaco descrita anteriormente pueden ser adicionalmente formuladas en numerosas formas de dosificacion final diferentes incluyendo, pero no limitandose a, un liquido, suspension liquida, gel, capsula, capsula de gelatina blanda, tableta, tableta masticable, tableta triturable, tableta de disolucion rapida, o unidad de uso en saquito o capsula para reconstitucion.
MXPA05008033A 2003-01-28 2004-01-28 Composiciones de milnacipran en forma de multiparticulas para administracion oral. MXPA05008033A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44323703P 2003-01-28 2003-01-28
US44361803P 2003-01-29 2003-01-29
US45899303P 2003-03-28 2003-03-28
US46847003P 2003-05-06 2003-05-06
US49006003P 2003-07-24 2003-07-24
PCT/US2004/002346 WO2004067039A1 (en) 2003-01-28 2004-01-28 Multiparticulate compositions of milnacipran for oral administration

Publications (1)

Publication Number Publication Date
MXPA05008033A true MXPA05008033A (es) 2006-04-28

Family

ID=32831196

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008033A MXPA05008033A (es) 2003-01-28 2004-01-28 Composiciones de milnacipran en forma de multiparticulas para administracion oral.

Country Status (7)

Country Link
US (1) US20040228830A1 (es)
EP (1) EP1592453A1 (es)
JP (1) JP2006515008A (es)
AU (1) AU2004207578B2 (es)
CA (1) CA2513893A1 (es)
MX (1) MXPA05008033A (es)
WO (1) WO2004067039A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2006506461A (ja) * 2002-10-25 2006-02-23 コルジウム ファーマシューティカル， インコーポレイテッド ミルナシプランのパルス型放出組成物
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
MX2007006120A (es) * 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
US20080095842A1 (en) * 2004-12-06 2008-04-24 Antarkar Amit K Rapidly Disintegrating Taste Masked Compositions and a Process for Its Preparations
EP1846040A2 (en) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
EP1834634A3 (en) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Pharmaceutical multiple-unit composition
DK2428205T3 (da) 2006-03-16 2012-10-22 Tris Pharma Inc Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
WO2009074995A1 (en) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Taste masked chewable compositions of sildenafil citrate
WO2011107922A2 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Extended release composition of milnacipran
WO2011107921A2 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Modified release composition of milnacipran
JP2013536832A (ja) * 2010-08-30 2013-09-26 ルピン・リミテッド ミルナシプランの制御放出医薬組成物
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
IN2014MN01901A (es) * 2012-03-02 2015-07-10 Rhodes Pharmaceuticals Lp
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
RS61024B1 (sr) * 2016-10-31 2020-12-31 Neurim Pharma 1991 Mini-tablete melatonina i postupak za njihovu proizvodnju
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4322311A (en) * 1978-08-04 1982-03-30 Damon Corporation Process for producing controlled porosity microcapsules
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4367741A (en) * 1980-12-22 1983-01-11 Alza Corporation Dispenser powered by cross-linked hydrophilic polymer grafted to hydrophilic polymer
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US4428925A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US4505890A (en) * 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US4650827A (en) * 1983-11-02 1987-03-17 Allied Corporation Stable water-in-oil emulsions
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4822619A (en) * 1987-02-18 1989-04-18 Ionor, Inc. Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
ATE79029T1 (de) * 1989-02-11 1992-08-15 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5861166A (en) * 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
AU650113B2 (en) * 1991-04-05 1994-06-09 Eli Lilly And Company Sustained release capsule and formulations
AU1560692A (en) * 1991-04-08 1992-11-02 Nippon Shinyaku Co. Ltd. Capsule
EP0664118B1 (en) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5292533A (en) * 1992-03-27 1994-03-08 Micro Flo Co. Controlled release microcapsules
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
DE4408326A1 (de) * 1994-03-11 1995-09-14 Hexal Pharma Gmbh Retardtablette mit einem Gehalt an Diclofenac-Na
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
DE69917000T2 (de) * 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
CA2332253A1 (en) * 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2000040224A1 (en) * 1999-01-07 2000-07-13 Elan Corporation, Plc Multiparticulate oral dosage forms
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
JP3797605B2 (ja) * 2002-03-20 2006-07-19 旭化成ファーマ株式会社 粒状被覆製剤の製造方法
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran

Also Published As

Publication number Publication date
CA2513893A1 (en) 2004-08-12
WO2004067039A1 (en) 2004-08-12
EP1592453A1 (en) 2005-11-09
JP2006515008A (ja) 2006-05-18
AU2004207578B2 (en) 2007-06-28
AU2004207578A1 (en) 2004-08-12
US20040228830A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
MXPA05008033A (es) Composiciones de milnacipran en forma de multiparticulas para administracion oral.
AU2001255509B2 (en) Taste masking coating composition
KANTOR Ibuprofen
JP5192816B2 (ja) 非ゼラチン軟質カプセルシステム
ES2582942T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US6663893B2 (en) Taste masking coating composition
TW464513B (en) Controlled release or delayed release formulation containing paroxetine
GEP20032912B (en) Enteric Coated Pharmaceutical Tablets and Method of Manufacturing
PT1492511E (pt) Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
CA2633924A1 (en) Gastric reflux resistant dosage forms
JPWO2006070578A1 (ja) 硬カプセルのバンドシール
HRP20100127T1 (hr) Višečestični oblici
JPS63139128A (ja) Ｌ―ドーパ含有組成物
JPH11503163A (ja) 低温溶融性薬物と制御放出のための添加物との均質混合物
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
CA2121038C (en) Oral preparation for release in lower digestive tracts
ES2288152T3 (es) Preparaciones solidas que contienen polvo de quitosano y procedimiento de produccion asociado.
ES2671843T3 (es) Composiciones líquidas para cápsulas blandas de liberación prolongada y su procedimiento de fabricación
JP2004507487A (ja) 腸疾患治療薬
JP2011516544A5 (es)
TW201127816A (en) 4-methylpyrazole formulations
JPH06256170A (ja) 被覆製剤
KR101680925B1 (ko) 불쾌미 마스킹 입자 및 이것을 함유하는 경구제제
MXPA06012738A (es) Composiciones farmaceuticas encapsuladas en gel blando que comprenden ingredientes activos concentrados.
Bhoyar et al. An overview of a gastro retentive floating drug delivery system